MaxCyte, Inc. (LON:MXCT – Get Free Report) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 344.50 ($4.29) and traded as low as GBX 311.13 ($3.87). MaxCyte shares last traded at GBX 313 ($3.90), with a volume of 111 shares traded.
MaxCyte Price Performance
The firm has a fifty day moving average of GBX 343 and a 200 day moving average of GBX 337.74. The company has a market capitalization of £329.05 million, a P/E ratio of -1,079.31 and a beta of 1.04. The company has a current ratio of 10.65, a quick ratio of 14.38 and a debt-to-equity ratio of 8.07.
Insider Buying and Selling
In related news, insider John Johnston sold 5,000 shares of MaxCyte stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of GBX 441 ($5.49), for a total value of £22,050 ($27,449.27). 1.30% of the stock is owned by corporate insiders.
About MaxCyte
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Further Reading
- Five stocks we like better than MaxCyte
- What Are Dividend Achievers? An Introduction
- Comprehensive PepsiCo Stock Analysis
- How to Evaluate a Stock Before Buying
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What is a Special Dividend?
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.